Last update Dec. 4, 2020
Very Low Risk
Antiviral HIV protease inhibitor. Used and associated with lopinavir, in the treatment of HIV/AIDS.
It has been used experimentally in the treatment of the COVID-19 coronavirus (Li 2020, Lim 2020, SEFH 2020).
Oral administration in two daily doses.
Its pharmacokinetic data (moderately high molecular weight and very high percentage of protein binding) explain the negligible transfer into milk observed (Corbett 2014, Palombi 2012).
The plasma levels of infants whose mothers took it were undetectable (Corbett 2014) or very low (Gandhi 2013, Palombi 2012).
According to the policy adopted by the health authorities of each country, breastfeeding in mothers with HIV/AIDS may or may not be recommended.
With highly active antiretroviral therapy (HAART), the HIV viral load can be reduced to zero, reducing the risk of HIV transmission through breastfeeding to levels similar to those of formula feeding.
We do not have alternatives for Ritonavir since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM